newsfilter
← Latest News
GlobeNewswire·

Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

- Company is leveraging proprietary cell-targeted lipid nanoparticle delivery to develop wholly-owned in vivo program for sickle cell disease and beta-thalassemia - Development of breakthrough immune-quiet DNA for